|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 5/07/20 Revance Therapeutics, Inc. 10-Q 3/31/20 59:5.6M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.00M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
53: R1 Cover Page HTML 73K
23: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 107K
16: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 38K
(Parenthetical)
33: R4 Condensed Consolidated Statement of Operations and HTML 67K
Comprehensive Loss (Unaudited)
52: R5 Condensed Consolidated Statements of Shareholders' HTML 79K
Equity (Unaudited) Condensed Consolidated
Statements of Shareholders' Equity (Unaudited)
22: R6 Condensed Consolidated Statements of Shareholders' HTML 23K
Equity (Unaudited) Consolidated Statements of
Stockholders' Equity (Parenthetical)
15: R7 Condensed Consolidated Statements of Cash Flows HTML 120K
(Unaudited)
32: R8 The Company and Summary of Significant Accounting HTML 37K
Policies
54: R9 Revenue HTML 35K
26: R10 Cash Equivalents and Short-Term Investments HTML 80K
18: R11 Filler Distribution Agreement HTML 31K
40: R12 Derivative Liability HTML 24K
59: R13 Leases HTML 44K
25: R14 Convertible Senior Notes HTML 52K
17: R15 Stockholders' Equity and Stock-Based Compensation HTML 48K
39: R16 Fair Value Measurements HTML 93K
58: R17 Commitments and Contingencies HTML 29K
24: R18 The Company and Summary of Significant Accounting HTML 44K
Policies (Policies)
19: R19 Cash Equivalents and Short-Term Investments HTML 78K
(Tables)
42: R20 Filler Distribution Agreement (Tables) HTML 27K
47: R21 Leases Leases (Tables) HTML 47K
30: R22 Convertible Senior Notes (Tables) HTML 32K
12: R23 Stockholders' Equity and Stock-Based Compensation HTML 41K
(Tables)
41: R24 Fair Value Measurements (Tables) HTML 93K
46: R25 The Company and Summary of Significant Accounting HTML 38K
Policies- Additional Information (Detail)
29: R26 Revenue (Details) HTML 56K
11: R27 Cash Equivalents and Short-Term Investments HTML 53K
(Detail)
43: R28 Filler Distribution Agreement - Narrative HTML 32K
(Details)
45: R29 Filler Distribution Agreement - Distributions HTML 30K
Rights (Details)
55: R30 Derivative Liability - Additional Information HTML 37K
(Detail)
36: R31 Leases Leases (Details) HTML 23K
20: R32 Leases Leases - Operating Lease Costs (Details) HTML 26K
27: R33 Leases Leases - Operating Lease Liability HTML 41K
Maturities (Details)
56: R34 Leases Leases - Supplemental Cash Flow Information HTML 24K
(Details)
37: R35 Convertible Senior Notes (Details) HTML 68K
21: R36 Convertible Senior Notes - Interest Expense HTML 44K
(Details)
28: R37 Convertible Senior Notes - Carrying Amount of HTML 32K
Liability Component (Details)
57: R38 Convertible Senior Notes - Capped Call HTML 33K
Transactions (Details)
35: R39 Stockholders' Equity and Stock-Based Compensation HTML 80K
- Stock Option Plan Additional Information
(Details)
48: R40 Stockholders' Equity and Stock-Based Compensation HTML 34K
- Common Stock Equivalents Excluded from the
Calculation of Earnings per Share (Details)
44: R41 Stockholders' Equity and Stock-Based Compensation HTML 27K
- Stock Option Plan Schedule of Stock-based
Compensation Expense (Details)
13: R42 Fair Value Measurements - Schedule of Fair Value HTML 87K
of Financial Instruments (Detail)
31: R43 Fair Value Measurements - Summary of Changes in HTML 30K
Fair Value of Financial Instruments (Detail)
51: R44 Commitments and Contingencies - Additional HTML 40K
Information (Detail)
34: XML IDEA XML File -- Filing Summary XML 102K
14: XML XBRL Instance -- rvncq12010-q_htm XML 1.12M
50: EXCEL IDEA Workbook of Financial Reports XLSX 57K
7: EX-101.CAL XBRL Calculations -- rvnc-20200331_cal XML 161K
8: EX-101.DEF XBRL Definitions -- rvnc-20200331_def XML 410K
9: EX-101.LAB XBRL Labels -- rvnc-20200331_lab XML 1.14M
10: EX-101.PRE XBRL Presentations -- rvnc-20200331_pre XML 663K
6: EX-101.SCH XBRL Schema -- rvnc-20200331 XSD 113K
38: JSON XBRL Instance as JSON Data -- MetaLinks 252± 382K
49: ZIP XBRL Zipped Folder -- 0001479290-20-000058-xbrl Zip 255K
 | Download this Microsoft® Excel® .xlsx workbook |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/14/22 Revance Therapeutics, Inc. 424B5 2:545K Donnelley … Solutions/FA 9/12/22 Revance Therapeutics, Inc. 424B5 1:519K Donnelley … Solutions/FA 5/10/22 Revance Therapeutics, Inc. 424B5 2:504K Donnelley … Solutions/FA 1/29/21 Revance Therapeutics, Inc. S-8 1/29/21 3:137K 11/27/20 Revance Therapeutics, Inc. S-3ASR 11/27/20 7:1.1M Donnelley … Solutions/FA |